JP2023530663A5 - - Google Patents

Info

Publication number
JP2023530663A5
JP2023530663A5 JP2022576392A JP2022576392A JP2023530663A5 JP 2023530663 A5 JP2023530663 A5 JP 2023530663A5 JP 2022576392 A JP2022576392 A JP 2022576392A JP 2022576392 A JP2022576392 A JP 2022576392A JP 2023530663 A5 JP2023530663 A5 JP 2023530663A5
Authority
JP
Japan
Prior art keywords
amino acid
antigen
binding protein
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022576392A
Other languages
English (en)
Japanese (ja)
Other versions
JP7798805B2 (ja
JP2023530663A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/036347 external-priority patent/WO2021252455A1/en
Publication of JP2023530663A publication Critical patent/JP2023530663A/ja
Publication of JP2023530663A5 publication Critical patent/JP2023530663A5/ja
Application granted granted Critical
Publication of JP7798805B2 publication Critical patent/JP7798805B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022576392A 2020-06-08 2021-06-08 抗TGFβ抗体及びその治療的使用 Active JP7798805B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063036092P 2020-06-08 2020-06-08
US63/036,092 2020-06-08
PCT/US2021/036347 WO2021252455A1 (en) 2020-06-08 2021-06-08 ANTI-TGFβ ANTIBODIES AND THERAPEUTIC USES THEREOF

Publications (3)

Publication Number Publication Date
JP2023530663A JP2023530663A (ja) 2023-07-19
JP2023530663A5 true JP2023530663A5 (enExample) 2024-12-16
JP7798805B2 JP7798805B2 (ja) 2026-01-14

Family

ID=76708478

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022576392A Active JP7798805B2 (ja) 2020-06-08 2021-06-08 抗TGFβ抗体及びその治療的使用

Country Status (13)

Country Link
US (1) US20220119513A1 (enExample)
EP (1) EP4161654A1 (enExample)
JP (1) JP7798805B2 (enExample)
KR (1) KR20230022974A (enExample)
CN (1) CN115803342A (enExample)
AU (1) AU2021287868A1 (enExample)
BR (1) BR112022024195A2 (enExample)
CA (1) CA3186707A1 (enExample)
CO (1) CO2023000068A2 (enExample)
DK (1) DK202370008A1 (enExample)
MX (1) MX2022015609A (enExample)
PH (1) PH12022500030A1 (enExample)
WO (1) WO2021252455A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230038522A (ko) 2020-07-10 2023-03-20 인베티엑스 인코포레이티드 고양이에서 치료제의 반감기를 증가시키기 위한 조성물 및 사용 방법
MX2023003624A (es) 2020-09-28 2023-04-11 Zoetis Services Llc Variantes de anticuerpos caninos.
CA3232382A1 (en) * 2021-09-27 2023-03-30 Zoetis Services Llc Anti- tgf.beta.1,2,3 antibodies and therapeutic uses thereof
WO2024145280A2 (en) 2022-12-27 2024-07-04 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
US20240209096A1 (en) 2022-12-27 2024-06-27 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
AU2024210302A1 (en) 2023-01-20 2025-09-04 Invetx, Inc. Bispecific binding agents for use in companion animals
CN117106082B (zh) * 2023-09-15 2024-10-29 成都蓉生药业有限责任公司 一种抗TGFβ的人源化纳米抗体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5350576A (en) 1991-09-13 1994-09-27 Mycogen Corporation Bacillus thuringiensis isolates for controlling acarides
US6194167B1 (en) 1997-02-18 2001-02-27 Washington State University Research Foundation ω-3 fatty acid desaturase
MXPA01009363A (es) 1999-03-18 2002-06-04 Merck Patent Gmbh Proteina para bloquear la adhesion de plaquetas.
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EP1130098A3 (en) 2000-02-29 2003-09-10 Pfizer Products Inc. Mammalian osteoregulins
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
US7261890B2 (en) 2001-12-21 2007-08-28 Idexx Laboratories, Inc. Methods for using canine immunoglobulin variable domains and caninized antibodies
EP1966243B1 (en) * 2005-12-23 2012-02-15 Eli Lilly And Company Tgf-beta binding antibodies
US9518112B2 (en) * 2012-03-08 2016-12-13 Ludwig Institute For Cancer Research Ltd TGF-β1 specific antibodies and methods and uses thereof
LT2971048T (lt) * 2013-03-11 2019-02-25 Genzyme Corporation Inžineriniu būdu gauti anti-tgf-beta antikūnai ir antigeną surišantys fragmentai
TWI733661B (zh) * 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子-β1的經修飾IgG抗體
TWI726870B (zh) * 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β1的scFv-Fc二聚體
TWI787230B (zh) * 2017-01-20 2022-12-21 法商賽諾菲公司 抗TGF-β抗體及其用途
WO2018208670A1 (en) * 2017-05-08 2018-11-15 Trustees Of Tufts College EXTRACELLULAR VESICLES COMPRISING MEMBRANE-TETHERED TGF-β, COMPOSITIONS AND METHODS OF USE THEREOF
CN113613725B (zh) * 2018-11-05 2025-09-23 路德维格癌症研究所有限公司 人源化和变体TGF-β1特异性抗体及其方法和用途

Similar Documents

Publication Publication Date Title
JP2023530663A5 (enExample)
JP7041516B2 (ja) 共通軽鎖を有する二重特異性抗体又は抗体混合物
JP2022079549A5 (enExample)
JP2020505919A5 (enExample)
CN111018987B (zh) 一种能与人内皮素受体特异性结合的抗体及其应用
JP2008542278A5 (enExample)
JP7533897B2 (ja) 融合タンパク質およびその使用
RU2015144105A (ru) Антитела к гепсидину и их применения
HRP20110187T1 (hr) Multispecifične deimunizirane tvari koje vežu cd3
JP2022540083A5 (enExample)
JP2024531409A5 (enExample)
JP2010509931A5 (enExample)
JP2013539369A5 (enExample)
CN110869390A (zh) 抗pd-l1抗体及其用途
JPWO2020059847A5 (enExample)
JP2023093753A5 (enExample)
JP2020505927A5 (enExample)
CN113354730B (zh) 一种抗新型冠状病毒的单克隆抗体及其应用
JP2023506750A5 (enExample)
CN1381461A (zh) 抗人肝癌单克隆抗体HAb18轻、重链可变区基因及其应用
JP2023508674A5 (enExample)
JP2021517459A5 (enExample)
CN116836269A (zh) 抗呼吸道合胞病毒的单克隆抗体及其应用
JP2023549851A5 (enExample)
JP2023524811A5 (enExample)